Evaluation of the Epidemiological Situation B.canis Infections in Human and B.canis Seroprevalence in Diyarbakir, Turkey
Science Journal of Public Health
Volume 2, Issue 2, March 2014, Pages: 87-91
Received: Jan. 21, 2014; Published: Mar. 10, 2014
Views 2692      Downloads 107
Authors
Fulya BAYINDIR BİLMAN, Diyarbakır Training and Research Hospital, Department of Microbiology, Diyarbakır, Türkiye
Sevil ERDENLİĞ GÜRBİLEK, Harran Univercity, Faculty of Veterinary Medicine, Department of Microbiology, Urfa, Türkiye
Mine TURHANOĞLU, Diyarbakır Training and Research Hospital, Department of Microbiology, Diyarbakır, Türkiye
Article Tools
PDF
Follow on us
Abstract
Brucella canis, which is an infectious agent of dogs, rarely causes disease in human, and displays asymptomatic or subclinical course. Carnivors are natural host for B.canis infection. Considering the limited number of studies investigating the seroprevalence of B.canis in the population in Turkey, a serologic study was planned to investigate of B.canis infection. For this reason, serum samples from the patients who were admitted to Diyarbakır Training and Research Hospital with various reasons other than complaints of an infectious disease were screened using B.canis antigen prepared in Microbiology Laboratory of Harran Univercity, Faculty of Veterinary Medicine to identify the prevalence of this infection in the Southeastern region of Turkey. The serological tests for brucellosis caused by smooth species, (B.abortus, B.suis and B.melitensis etc.) are based on the reaction of antibodies against smooth-lipopolysaccharide (S-LPS) on the bacterial cell wall. But B.canis has a rough-lipopolysaccharide (R-LPS) in its cell wall. Therefore detection of antibodies against R-LPS requires use of specific antigen in serological diagnosis of Brucella infection caused by rough Brucella strains. Unfortunately, a standardized slide agglutination test (SAT) antigen that would serologically detect B.canis and other rough Brucella strains is not commercially available. The present study aimed to investigate seropositivity rate in the patients via SAT using B.canis antigen prepared in laboratory. The study comprised 2100 serum samples obtained from patients (range of age: 16-75 years; 1340 females and 760 males), who presented to various policlinics of Diyarbakır Training and Research Hospital between 01 April 2013 and 31 June 2013. Serum samples were first examined serologically using Standard Rose Bengal test antigen (Refik Saydam Hygiene Institute, Turkey) for the infection with smooth Brucella species, and then negative serum samples were included in the study. Of the 2100 serum samples screened for B.canis using standard slide agglutination test, 33 (1.57%) gave positive result. Fourteen of these 33 patients were female and 17 were male. Seven (21%) of these subjects reported that they had dog in a period of their lives. Their personal history revealed no autoimmune, metabolic or immunosuppressive disease in the past. It is concluded that, B.canis should be considered in the case of fever and infection of unknown origin, particularly in those with the history of contact with dogs. It was also concluded that the development of standardized rapid screening tests is needed for routine serologic diagnosis of brucellosis caused by rough Brucella strains.
Keywords
Brucella canis, Seroprevalence, Slide Agglutination Test, Guillain–Barré Syndrome
To cite this article
Fulya BAYINDIR BİLMAN, Sevil ERDENLİĞ GÜRBİLEK, Mine TURHANOĞLU, Evaluation of the Epidemiological Situation B.canis Infections in Human and B.canis Seroprevalence in Diyarbakir, Turkey, Science Journal of Public Health. Vol. 2, No. 2, 2014, pp. 87-91. doi: 10.11648/j.sjph.20140202.17
References
[1]
Lindquist D, Chu MC, Probert WWS. Francisella and Brucella. In: Manual of Clinical Microbiology, 9th ed, Murray PR, Baron EJO, Jorgensen JH, et al (Eds), ASM Press, Washington, DC 2007. p.824.
[2]
Young EJ. Brucella species, pp: 2921-5. In: Mandell GL, Bennett JE, Dolin R (eds), Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 2009, 7th ed. Churchill Livingstone, Philadelphia.
[3]
Millar B, Altwegg M, Raoult D, Moore JE. Culture-negative Endocarditis–Causes, Diagnosis and Treatment. Rev med Micro 2000;11(2)59-75.
[4]
Center for Food Security and Public Health. Canine Brucellosis: Brucella canis.2011. (www.cfsph.iastate.edu/Factsheets/pdfs/brucellosis_canis.pdf , Accessed November, 2011)
[5]
Lucero NE, Corazza R, Almuzara MN, Reynes E, Escobar GI, Boeri E, et al. Human Brucella canis outbreak linked to infection in dogs. Epidemiol Infect 2010; 138 (2): 280-285.
[6]
Wallach JC, Giambartolomei GH, Baldi PC, and Fossati CA. Human Infection with M-Strain of Brucella canis. Emerging Infectious Diseases, www.cdc.gov/eid, 2004; 10(1):146-148.
[7]
Nomura A, Imaoka K, Imanishi H, Shimizu H, Nagura F, Maeda K, et al. Human Brucella canis Infections Diagnosed by Blood Culture Emerging Infectious Diseases, www.cdc.gov/eid, 2010; 16(7): 1183-1184. DOI: 10.3201/eid1607.090209
[8]
Javeri H, Jamieson S, Sehgal R, Cadena J. Brucella canis peritonitis. Infection, 2013; DOI 10.1007/s15010-013-0505-0.
[9]
Ying W, Nguyen MQ and Jahre JA. Brucella canis endocarditis: Case report. Clin Infect Dis 1999; 29: 1593–1594.
[10]
Alton GG, Jones LM, Angus RD, Verger JM. Brucella canis, pp: 169-174. In: Techniques for the Brucellosis Laboratory. 1988, Institut National de la Recherche Agronomique, Paris, France.
[11]
Sayan M, Erdenlig S, Stack J, Kilic S, Guducuoglu H, Aksoy Y, et al. A serological diagnostic survey for Brucella canis infection in Turkish patients with brucellosis-like symptoms. Jpn J Infect Dis 2011; 64 (6): 516-519.
[12]
Sayan M, Erdenliğ S, Etiler N. Investigation of Brucella canis seropositivity by in-house slide agglutination test antigen in healthy blood donors. Mikrobiyol Bul 2011; 45 (4): 655-663.
[13]
Centers for Disease Control and Prevention (CDC). Brucellosis. Available at: http://www.cdc.gov/ncidod/dbmd/diseaseinfo/brucellosis_t.html/ accession date: January 2014)
[14]
Carmichael LE, Zoha SJ, FloresCastro R. Biological properties and dog response to a variant (M-) strain of Brucella canis. Dev Biol Stand 1984; 56: 649–656.
[15]
Lucero NE, Escobar GI, Ayala SM, Jacob N. Diagnosis of human brucellosis caused byBrucella canis. J Med Microbiol 2005;54: 457–461.
[16]
Carmicheal LE, Joubert JC: A rapid slide agglutination test for the serodiagnosis of Brucella canis infection that employs a variant (M-) organism as antigen. Cornell Vet 1987; 77 (1): 3-12.
[17]
Marzetti S, Carranza C, Roncallo M, Escobar GI, Lucero NE. Recent trends in human Brucella canis infection. Comp Immunol Microbiol Infect Dis 2013; 36 (1): 55-61.
[18]
Lucero NE, Escobar GI, Ayala SM, Jacob N. Diagnosis of human brucellosis caused by Brucella canis. J Med Microbiol 2005; 54: 457–461.
[19]
Turfaner Erturk N, Karter Y, Tungkale A, Sipahioglu F. Gaucher disease and brucella: just a mere coincidence? Genetic Counseling 2003; 14 (3): 363–365.
[20]
Babamahmoodi F, Babamahmoodi A. Brucellosis, presenting with Guillain–Barré syndrome. J Global Infect Dis 2011; 3 (4): 390–392.
[21]
Sharafoddin ZN, Keyhani FM. A case of neurobrucellosis mimicking Guillain–Barre syndrome. J Isfahan Med School 2007; 25: 111–115.
[22]
Namiduru M, Karaoglan I, Yilmaz M. Giullain–Barré syndrome associated with acute neurobrucellosis. Int J Clin Pract 2003; 57: 919–920
[23]
Montalvo R, García Y, Navincopa M, Ticona E, Chávez G, Moore DA. Guillain Barré syndrome in association with Brucellosis. Rev Peru Med Exp Salud Publica 2010; 27: 292–295.
[24]
Wallach JC, Giambartolomei GH, and Baldi PC. Human infection with M-strain of Brucella canis. Emerg Infect Dis 2004; 10: 146–148
[25]
Kimura M, Imaoka K, Suzuki M, Kamiyama T, Yamada A. Evaluation of a microplate agglutination test (MAT) for serological diagnosis of canine brucellosis. J Vet Med Sci 2008; 70: 707–709.
[26]
Polt SS, Dismukes WE. Human brucellosis caused by Brucella canis. Ann Intern Med 1982; 97 (5): 717-719.
[27]
Flores-Castro R and Segura R. A serological and bacteriological survey of canine brucellosis in Mexico. Cornell Vet 1976; 66: 347–352.
[28]
Carmichael LE, Flores-Castro R and Zoha S. Brucellosis caused by Brucella canis: an Update of Infection in Animals and in Humans. Geneva: World Health Organization 1980. Document WHO/BRUC./80.361 WHO/ZOON./80.135
[29]
Lewis GE and Anderson JK. The incidence of Brucella canis antibodies in sera of military recruits. Am J Public Health 1973; 63: 204–205.
[30]
Hoff GL and Schneider NJ. Serologic survey for agglutinins to Brucella canis in Florida residents. Am J Trop Med Hyg 1975; 24: 157–159.
[31]
Diker S, İstanbulluoğlu E, Ayhan H, Soysal G. A serologic study of human Brucella canis infections in the Bursa region. Mikrobiyol Bul 1984; 18 (4): 203-207.
[32]
Köksal F, Akan E, Başlamışlı L, Diker S, Yiğit S, Özcan K. Antibody levels to B.abortus, B.canis and C.burnetti in the sera of patients with brucellosis-like symptoms. Mikrobiyol Bul 1988; 22 (2): 132-141.
[33]
Köylü Ö, Aras Z, Uçan US. The seroprevalence of Brucella canis infection in a risky human population in province Konya. Turkish J Infect 2009; 23 (2): 73-77.
[34]
Clausse M, Díaz AG, Ghersi G, Zylberman V, Cassataro J, Giambartolomei GG, et al. The vaccine candidate BLSOmp31 protects mice against Brucella canis infections. Vaccine, 2013 Jul 30. doi: pii: S0264-410X(13)00984-5.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186